Jeremy Skillington
Chief Executive Officer at POOLBEG PHARMA PLC
Net worth: 152 364 $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Luke O'Neill | M | 60 | - | |
| Cathal Friel | M | 59 | 4 years | |
| Brendan Buckley | M | 73 | 1 years | |
| Ian O'Connell | M | 37 | 3 years | |
| Eddie Gibson | M | 50 | 3 years | |
| Bernd Seizinger | M | 67 |
TriMod Therapeutics Ltd.
 TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | 13 years |
| John G. Armstrong | M | - |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | - |
| Ross Crockett | M | - | 3 years | |
| David Allmond | M | 54 | 1 years | |
| John McEvoy | M | 37 | - | |
| Bruno Speder | M | - | 2 years | |
| Carol Dalton | F | - | 3 years | |
| Laura Maher | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Patrick Ashe | M | 59 | - | |
| Kingston H. G. Mills | M | - |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | - |
| David Hurley | M | - |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | - |
| Salim Hamir | M | - | - | |
| David English | M | - | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 14 | 77.78% |
| Ireland | 4 | 22.22% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeremy Skillington
- Personal Network
